An Unusual Phenotype of Multiple Endocrine Neoplasia Type 1 with a Small Intestine Neuroendocrine Tumor Associated with Large Deletion of the MEN1 Gene Abstract #1438

Introduction: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant inherited tumor syndrome that is caused by germline mutations in the Menin suppressor gene on chromosome 11q13. Small intestine neuroendocrine neoplasias (SI-NEN) are currently not considered to be part of the phenotype of the MEN1-syndrome.
Aim(s): Investigating a connection between an unusual and aggressive phenotype of the MEN1 syndrome with SI-NEN and the occurence of large deletion of the MEN1 gene.
Materials and methods: Besides conventional mutation analysis of MEN1 patients modern techniques as Multiplex-ligation-dependent probe amplification (MLPA) were used for the search for larger gene deletions. Ga68-Dotatoc PET/CT was used as an imaging method to detect SI-NENs
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan

To read results and conclusion, please login ...

Further abstracts you may be interested in

#2707 Investigating the Crosstalk between MEN1, p53 and Notch Reveals Biomarkers of Formation of Primary Pancreatic Neuroendocrine Tumors
Introduction: Pancreatic neuroendocrine tumors (PNETs) comprise a heterogeneous group of endocrine tumors. Previous studies showed that mutations of p53 are extremely rare; whereas genetic changes of MEN1 frequently occur and are correlated with poor prognosis in PNET. Still, their roles in tumorigenesis remain elusive.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Signaling pathways, receptors, biomarkers
Presenting Author: Dr Ylenia Capodanno
#1327 Is Screening of Young Asymptomatic MEN1 Patients Necessary?
Introduction: Recent clinical practice guidelines recommend that routine screening of MEN1 mutation carriers should start at the age of 5 years to detect MEN1-associated tumors which is controversial in the scientific community.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Clinical cases/reports
Presenting Author: MD Jerena Manoharan
Keywords: Screening, MEN1
#2936 Mutational Landscape of 109 High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms G3
Introduction: Gastroenteropancreatic (GEP) neuroendocrine neoplasms (NEN) G3 are rare with a poor outcome. Molecular data for GEP NEN G3 is limited and the 2019 WHO classification is based on morphology and proliferation rate.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Basic Science - Genetics, epigenetics, miRNAs, Omics
Presenting Author: MSc Andreas Venizelos
#3079 Novel Symptoms and Therapy of Multiple Endocrine Neoplasia Type 1
Introduction: MEN1 is a rare autosomal inherited disease with hallmark of hyperparathyroidism, duodenopancreatic NENs and pituitary tumor.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Case reports
Presenting Author: Jian-An Bai
Authors: Bai J A, Tang Q, ...
#2795 Molecular Correlation of the Activity of Evofosfamide (EVO) in Combination with Sunitinib (SUN) in Pancreatic Neuroendocrine Tumors (pNETs) in the SUNEVO GETNE Trial
Introduction: MEN1, DAXX, ATRX, and PI3K/AKT/mTOR pathway genes are frequently mutated in pNETs. Sunitinib is approved and widely used in the metastatic setting but unfortunately, no validated predictive biomarker has been identified to guide therapy yet. The SUNEVO phase II trial of the Spanish Task Force Group for Neuroendocrine and Endocrine Tumours (GETNE) trial combined the pro-drug of EVO under SUN-induced hypoxic conditions.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Trials in Progress/Trials in Concept
Presenting Author: Dr. Enrique Grande